Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06701812 · ClinicalTrials.gov registry record · Phase 2
Digoxin Medulloblastoma Study
A Phase 2 study of Medulloblastoma and Medulloblastoma, Non-WNT/Non-SHH, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 15
- Study locations
NCT06701812 is a Phase 2 study of Medulloblastoma and Medulloblastoma, Non-WNT/Non-SHH that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 23 participants, below the 140-participant average among 29 other Medulloblastoma trials with a reported enrollment target (84% lower). The trial reports 15 study locations across 11 states.
The verdict
NCT06701812, a Phase 2 study of Medulloblastoma and Medulloblastoma, Non-WNT/Non-SHH, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Conditions Studied
Interventions
- DRUG Digoxin
Study Locations (15)
Florida
- Nemours Jacksonville - Jacksonville
- University of Miami - Miami
- Johns Hopkins All Children's - St. Petersburg
- St. Joseph's Children's Hospital - Tampa
North Carolina
- UNC Lineberger Comprehensive Cancer Center - Chapel Hill
- Levine Cancer Institute - Charlotte
Alabama
- University of Alabama at Birmingham Children's of Alabama - Birmingham
Arkansas
- Arkansas Childrens Hospital - Little Rock
Connecticut
- Connecticut Children's Medical Center - Hartford
District of Columbia
- Children's National Medical Center - Washington D.C.
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
Missouri
- Washington University St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06701812
The ClinicalTrials.gov registry entry for NCT06701812 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 29 other Medulloblastoma trials with a reported enrollment target (84% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Medulloblastoma appearing as the primary indexed condition, and to 1 intervention - of which Digoxin is the first listed.
NCT06701812 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Florida, North Carolina, Alabama.
Frequently Asked Questions
What is clinical trial NCT06701812 about?
NCT06701812 is a clinical study titled "Digoxin Medulloblastoma Study". The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
What is the current status of trial NCT06701812?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2026-01-15. Estimated completion is 2027-02.
What conditions does trial NCT06701812 study?
This clinical trial studies the following conditions: Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH.
What interventions are being tested in trial NCT06701812?
The interventions under investigation include: Digoxin (DRUG).
Who is sponsoring clinical trial NCT06701812?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06701812 being conducted?
This trial has 15 study locations across Alabama, Arkansas, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medulloblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
RECRUITING · Phase 2
-
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
RECRUITING · Phase 2
-
Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
ACTIVE NOT RECRUITING · Phase 2
-
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
ACTIVE NOT RECRUITING · Phase 2
-
Methionine PET/CT Studies In Patients With Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.